Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate to Severe Atopic Dermatitis: Including Adverse Events of Special Interest. J of Skin 2023, 7 (2), s143. https://doi.org/10.25251/skin.7.supp.143.